EVO
Price
$1.69Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
578.21M
Intraday BUY SELL Signals
GELS
Price
$0.42Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
4.72M
Intraday BUY SELL Signals
Interact to see
Advertisement

EVO vs GELS

EVO vs GELS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EVO vs. GELS commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and GELS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EVO with price predictions
Nov 10, 2026

EVO in upward trend: 10-day moving average broke above 50-day moving average on November 10, 2026

The 10-day moving average for EVO crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on EVO as a result. In 67 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 29 of 41 cases over the following month. The odds of a continued upward trend are 71%.

EVO moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +14.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 187 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 85 of 140 cases where EVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.

Bearish Trend Analysis

The 10-day RSI Indicator for EVO moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 15 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 58 cases where EVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

EVO broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (6.379). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (183.387).

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for GELS with price predictions
Nov 10, 2026

GELS's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GELS's RSI Indicator exited the oversold zone, 14 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for GELS just turned positive on October 27, 2026. Looking at past instances where GELS's MACD turned positive, the stock continued to rise in 16 of 19 cases over the following month. The odds of a continued upward trend are 84%.

Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where GELS advanced for three days, in 51 of 64 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GELS as a result. In 35 of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GELS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

GELS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for GELS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.589) is normal, around the industry mean (6.379). P/E Ratio (-1.236) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. GELS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GELS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
EVO: Fundamental Ratings
EVO
OUTLOOK RATING
1..100
23
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
2
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
EVOGELS
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
62%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
68%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (EVO: $1.69 vs. GELS: $0.42)
Brand notoriety: EVO and GELS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EVO: 55% vs. GELS: 2%
Market capitalization -- EVO: $578.21M vs. GELS: $4.72M
EVO [@Pharmaceuticals: Generic] is valued at $578.21M. GELS’s [@Pharmaceuticals: Generic] market capitalization is $4.72M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green while GELS’s FA Score has 2 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • GELS’s FA Score: 2 green, 3 red.
According to our system of comparison, GELS is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 6 TA indicator(s) are bullish while GELS’s TA Score has 4 bullish TA indicator(s).

  • EVO’s TA Score: 6 bullish, 4 bearish.
  • GELS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EVO is a better buy in the short-term than GELS.

Price Growth

EVO (@Pharmaceuticals: Generic) experienced а +9.03% price change this week, while GELS (@Pharmaceuticals: Generic) price change was -14.09% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-2.87%
SNDL - EVO
42%
Loosely correlated
-0.71%
PRGO - EVO
31%
Poorly correlated
-0.71%
SUPN - EVO
28%
Poorly correlated
+4.09%
ACET - EVO
26%
Poorly correlated
+0.33%
ACB - EVO
26%
Poorly correlated
-0.97%
More

GELS and

Correlation & Price change

A.I.dvisor tells us that GELS and SXTC have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GELS and SXTC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GELS
1D Price
Change %
GELS100%
-6.12%
SXTC - GELS
25%
Poorly correlated
-7.10%
HCM - GELS
24%
Poorly correlated
+0.39%
AMLX - GELS
23%
Poorly correlated
+2.32%
IRWD - GELS
23%
Poorly correlated
+2.78%
EVO - GELS
22%
Poorly correlated
-2.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INVH27.09-0.11
-0.40%
Invitation Homes
UNTY58.21-0.27
-0.46%
Unity Bancorp
EP2.42-0.02
-0.82%
Empire Petroleum Corp
ADMA12.67-0.12
-0.94%
ADMA Biologics
DLXY1.55-0.12
-7.19%
Delixy Holdings Ltd